本报讯(记者何文英)近日，国内家用医疗器械领军企业可孚医疗（301087）科技股份有限公司(简称"可 孚医疗")在生物传感技术领域取得重要突破，其研究成果以《Single-channel electrochemical biosensor for simultaneous monitoring of glucose and uric acid》(用于同步检测葡萄糖和尿酸的单通道电化学生物传感 器)为题，发表在生物传感领域国际顶级期刊《Biosensors and Bioelectronics》。 论文第一作者为可孚医疗生物传感与创新材料研究院副院长全昌云，通讯作者为徐斌杰院长和阳明辉教 授。这是可孚医疗科研团队首次在国际顶级期刊发表科研论文，标志着企业在关键核心传感技术自主创 新上实现重大进展。 据了解，《Biosensors and Bioelectronics》是英国出版商Elsevier旗下具有高影响力的国际期刊，也是生 物技术与生物传感器领域排名靠前的核心期刊，影响因子为10.5，SCI一区。 攻克单通道双指标检测难题 当前，我国糖尿病和高尿酸血症(痛风)患者规模庞大，不少人长期面临"双高"风险。传统 ...

Core Insights - The muscle-controlled prosthetics industry in China is projected to reach a market size of approximately 1.258 billion yuan in 2024, with a year-on-year growth of 10.25% [1][5]. Industry Overview - Muscle-controlled prosthetics utilize bioelectric signals generated by muscle contractions to control prosthetic movements, providing improved functionality for amputees [2]. - The industry has evolved significantly since its inception in 1963, with key technological advancements leading to the development of multi-degree-of-freedom prosthetics [3][4]. Industry Development History - The industry began with research at the Shanghai Institute of Physiology in 1963, leading to the first practical forearm prosthetic in 1970 and advancements in multi-degree-of-freedom prosthetics by 1979 [2][4]. - Significant milestones include the introduction of tactile feedback in 1988 and the development of advanced bionic hands in recent years, culminating in the recognition of domestic products on international platforms [2][4]. Industry Supply Chain - The upstream supply chain includes materials and components such as metal materials, myoelectric sensors, and microprocessors, while the midstream focuses on the research and manufacturing of muscle-controlled prosthetics [4]. - The downstream applications span medical rehabilitation, sports rehabilitation, and industrial operations, reflecting a growing demand for high-quality rehabilitation aids [4]. Market Size - The muscle-controlled prosthetics market is experiencing rapid growth, driven by technological advancements and increasing consumer spending on healthcare, with per capita healthcare expenditure in China projected to reach 2,547 yuan in 2024 [4][5]. Key Companies' Performance - The industry is characterized by a competitive landscape with established players like Shanghai Kosei and emerging companies like Aoyi Technology, which leverage technological innovations and policy support to capture market share [5][6]. - Aoyi Technology's OHand bionic hand has gained FDA/CE certification and is included in various subsidy programs, making it a cost-effective option for consumers [5][6]. Industry Development Trends 1. **Technological Innovation**: The integration of brain-machine interfaces and AI algorithms is expected to enhance the functionality and intelligence of muscle-controlled prosthetics, moving towards a model of "body extension" [8][9]. 2. **Personalized Customization**: Future prosthetics will focus on personalized solutions through 3D printing and biomechanical analysis, catering to individual user needs and expanding market reach [9][10]. 3. **Industry Chain Improvement**: The industry aims to establish a complete supply chain, enhancing production efficiency and standardization, while fostering collaboration between academia and industry to drive innovation [10].

Core Viewpoint - Sanofi Biologics (300298.SZ) currently does not have a dedicated testing product for detecting Chikungunya virus disease [1] Group 1: Company Overview - The company utilizes biosensor technology to develop, produce, and sell a series of rapid diagnostic products for chronic disease patients and healthcare professionals [1] - It also provides related professional services and digital health management for diabetes [1]